Valtoco® (diazepam) – Expanded indication
April 16, 2025 - Neurelis announced the FDA approval of Valtoco (diazepam), for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.
Top